NCT03440541 is a NA clinical trial of REGE pro in Psoriasis, sponsored by Egyptian Atomic Energy Authority.

Who is sponsoring NCT03440541?

NCT03440541 is sponsored by Egyptian Atomic Energy Authority.

What drugs are being tested in NCT03440541?

Interventions in NCT03440541: REGE pro.

Is NCT03440541 still recruiting?

NCT03440541 is currently completed. Last updated 27 June 2019.

Last reviewed 2019-06-27 · How we verify

NCT03440541

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment

Completed NA Last updated 27 June 2019

What this trial tests

NA trial testing REGE pro in Psoriasis in 22 participants. Completed in 8 April 2016.

Timeline

4 August 2015

Primary endpoint
13 February 2016

8 April 2016

Quick facts

Lead sponsor	Egyptian Atomic Energy Authority
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	22
Start date	4 August 2015
Primary completion	13 February 2016
Estimated completion	8 April 2016
Sites	1 location across Egypt

Drugs / interventions tested

REGE pro

Conditions studied

Psoriasis — all drugs for Psoriasis →

Sponsor

Egyptian Atomic Energy Authority — full company profile →

Who can join

Adults 20 to 40, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving Psoriasis Area and Severity Index (PASI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Psoriasis

Currently open trials in the same condition.

NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria · NA · recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis · recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO) · recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting
NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting

Other Egyptian Atomic Energy Authority trials

Trials by the same sponsor.

NCT06054646 — Evaluation of Microinjected Amnion-derived Collagen by Dermapen in the Smoothing of Skin Wrinkles · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03440541 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Egyptian Atomic Energy Authority
Last refreshed: 27 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03440541.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing